InterVenn BioSciences

InterVenn Biosciences is a private, pre-revenue diagnostics company developing a novel liquid biopsy platform based on clinical glycoproteomics. Its core technology, GlycoVision, combines liquid chromatography-tandem mass spectrometry (LC-MS/MS) with artificial intelligence to precisely quantify intact glycopeptides, unlocking a previously untapped layer of biology for biomarker discovery. The company is building a pipeline of diagnostic applications, with early research published in high-impact journals for cancers like colorectal carcinoma, and is positioning itself as a partner for biopharma and clinicians to enable earlier disease detection and personalized treatment strategies.

GlycoVision: An AI-powered, high-throughput glycoproteomics platform using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to precisely quantify intact glycopeptides for biomarker discovery and diagnostic development.

InterVenn competes in the broad liquid biopsy/diagnostics space against companies using genomics (e.g., Guardant Health, GRAIL) and proteomics. Its primary differentiation is its exclusive focus on clinical-scale glycoproteomics, a niche with few direct competitors, though it must prove its biomarkers offer clear advantages over established and emerging alternatives.